1. Auvelity, a treatment that is designed to improve symptoms of major depression in one week.
2. Lybalvi, which treats schizophrenia and bipolar 1 disorder.
3. Qelbree, which treats attention-deficit/hyperactivity disorder.
4. Azstarys, which treats attention-deficit/hyperactivity disorder.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
